DNAtrix, a biotechnology company, develops virus-driven immunotherapies for cancer, with an initial focus on glioblastoma. Its lead product, DNX-2401, is a modified cold virus that targets and kills cancer cells and was developed through more than a decade of research. DNAtrix plans to expand to treating other cancers, particularly those without many curative options in terms of conventional therapies.